<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33835497</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1097-4598</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>64</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Muscle &amp; nerve</Title>
          <ISOAbbreviation>Muscle Nerve</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Buprenorphine may be effective for treatment of paramyotonia congenita.</ArticleTitle>
        <Pagination>
          <StartPage>95</StartPage>
          <EndPage>99</EndPage>
          <MedlinePgn>95-99</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.27249</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION/AIMS">Paramyotonia congenita (PMC) is a skeletal muscle sodium channelopathy characterized by paradoxical myotonia, cold sensitivity, and exercise/cold-induced paralysis. Treatment with sodium-channel-blocking antiarrhythmic agents may expose patients to a risk of arrhythmia or may be poorly tolerated or ineffective. In this study we explored the effectiveness of non-antiarrhythmic sodium-channel blockers in two patients with PMC.</AbstractText>
          <AbstractText Label="METHODS">Earlier treatment with mexiletine was discontinued for gastrointestinal side effects in one of the patients and lack of clinical benefit in the other. One patient received lacosamide, ranolazine, and buprenorphine, and the other was given buprenorphine only. Drug efficacy was assessed by clinical scores, timed tests, and by long and short exercise tests.</AbstractText>
          <AbstractText Label="RESULTS">In both patients, buprenorphine improved pain scores by at least 50%, stiffness and weakness levels, and handgrip/eyelid-opening times. The fall in compound muscle action potential (CMAP) during short exercise normalized in both patients at baseline, and improved after cooling. During long exercise, one patient showed an earlier recovery of CMAP, and the other patient had a less severe decrease (&lt;60%). With buprenorphine, the fall in CMAP induced by cooling normalized in one patient (from -72% to -4%) and improved (from -49% to -37%) in the other patient.</AbstractText>
          <AbstractText Label="DISCUSSION">Buprenorphine showed promising results for the treatment of exercise-induced paralysis and cold intolerance in the two patients assessed. The exercise test may be useful for quantitative assessment of treatment response. Further studies on a larger number of patients, under carefully controlled conditions, should be considered to address the effectiveness and long-term tolerability of this therapeutic option.</AbstractText>
          <CopyrightInformation>© 2021 Wiley Periodicals LLC.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ravaglia</LastName>
            <ForeName>Sabrina</ForeName>
            <Initials>S</Initials>
            <Identifier Source="ORCID">0000-0001-8749-3706</Identifier>
            <AffiliationInfo>
              <Affiliation>IRCCS Mondino Foundation, Pavia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maggi</LastName>
            <ForeName>Lorenzo</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zito</LastName>
            <ForeName>Antonio</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>IRCCS Mondino Foundation, Pavia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arceri</LastName>
            <ForeName>Sebastiano</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>IRCCS Mondino Foundation, Pavia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gallotti</LastName>
            <ForeName>Pietro</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Istituto Clinico "Beato Matteo," Hospital Group San Donato, Vigevano, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Altamura</LastName>
            <ForeName>Concetta</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>Sezione di Farmacologia, Dipartimento di Scienze Biomediche e Oncologia Umana, Scuola di Medicina, Università degli Studi di Bari Aldo Moro, Bari, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Desaphy</LastName>
            <ForeName>Jean Francois</ForeName>
            <Initials>JF</Initials>
            <AffiliationInfo>
              <Affiliation>Sezione di Farmacologia, Dipartimento di Scienze Biomediche e Oncologia Umana, Scuola di Medicina, Università degli Studi di Bari Aldo Moro, Bari, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bernasconi</LastName>
            <ForeName>Pia</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alfonsi</LastName>
            <ForeName>Enrico</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>IRCCS Mondino Foundation, Pavia, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>04</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Muscle Nerve</MedlineTA>
        <NlmUniqueID>7803146</NlmUniqueID>
        <ISSNLinking>0148-639X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000701">Analgesics, Opioid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D062553">NAV1.4 Voltage-Gated Sodium Channel</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C106251">SCN4A protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>40D3SCR4GZ</RegistryNumber>
          <NameOfSubstance UI="D002047">Buprenorphine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000701" MajorTopicYN="N">Analgesics, Opioid</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002047" MajorTopicYN="N">Buprenorphine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005080" MajorTopicYN="N">Exercise Test</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020967" MajorTopicYN="N">Myotonic Disorders</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D062553" MajorTopicYN="N">NAV1.4 Voltage-Gated Sodium Channel</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">buprenorphine</Keyword>
        <Keyword MajorTopicYN="Y">exercise test</Keyword>
        <Keyword MajorTopicYN="Y">nondystrophic myotonia</Keyword>
        <Keyword MajorTopicYN="Y">paramyotonia congenita</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>9</Day>
          <Hour>12</Hour>
          <Minute>57</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33835497</ArticleId>
        <ArticleId IdType="doi">10.1002/mus.27249</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Statland JM, Barohn RJ. Muscle channelopathies: the nondystrophic myotonias and periodic paralyses. Continuum (Minneap Minn). 2013;19:1598-1614.</Citation>
        </Reference>
        <Reference>
          <Citation>Tan SV, Z'Graggen WJ, Hanna MG, Bostock H. In vivo assessment of muscle membrane properties in the sodium channel myotonias. Muscle Nerve. 2018;57:586-594.</Citation>
        </Reference>
        <Reference>
          <Citation>Heatwole CR, Statland JM, Logigian EL. The diagnosis and treatment of myotonic disorders. Muscle Nerve. 2013;47:632-648.</Citation>
        </Reference>
        <Reference>
          <Citation>Statland JM, Bundy BN, Wang Y, et al. Consortium for Clinical Investigation of Neurologic Channelopathies. Mexiletine for symptoms and signs of myotonia in nondystrophic myotonia: a randomized controlled trial. JAMA. 2012;308:1357-1365.</Citation>
        </Reference>
        <Reference>
          <Citation>Stunnenberg BC, Raaphorst J, Groenewoud HM, et al. Effect of mexiletine on muscle stiffness in patients with nondystrophic myotonia evaluated using aggregated N-of-1 trials. JAMA. 2018;320:2344-2353.</Citation>
        </Reference>
        <Reference>
          <Citation>Suetterlin KJ, Bugiardini E, Kaski JP, et al. Long-term safety and efficacy of mexiletine for patients with skeletal muscle channelopathies. JAMA Neurol. 2015;72:1531-1533.</Citation>
        </Reference>
        <Reference>
          <Citation>D'Mello S, Shum L. A review of the use of mexiletine in patients with myotonic dystrophy and non-dystrophic myotonia. Eur J Hosp Pharm. 2016;23:359-363.</Citation>
        </Reference>
        <Reference>
          <Citation>Novak KR, Norman J, Mitchell JR, et al. Sodium channel slow inactivation as a therapeutic target for myotonia congenita. Ann Neurol. 2015;77:320-322.</Citation>
        </Reference>
        <Reference>
          <Citation>El-Bizri N, Kahlig KM, Shyrock JC, et al. Ranolazine block of human Nav1.4 sodium channels and paramyotonia congenita mutants. Channels (Austin). 2011;5:161-172.</Citation>
        </Reference>
        <Reference>
          <Citation>Lorusso S, Kline D, Bartlett A, et al. Open-label trial of ranolazine for the treatment of paramyotonia congenita. Muscle Nerve. 2019;59:240-243.</Citation>
        </Reference>
        <Reference>
          <Citation>Andersen G, Hedermann G, Witting N, et al. The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study. Brain. 2017;140:2295-2305.</Citation>
        </Reference>
        <Reference>
          <Citation>Stoetzer C, Martell C, de la Roche J, Leffler A. Inhibition of voltage-gated Na+ channels by bupivacaine is enhanced by the adjuvants buprenorphine, ketamine, and clonidine. Reg Anesth Pain Med. 2017;42:462-468.</Citation>
        </Reference>
        <Reference>
          <Citation>Griggs RC, Sansone V, Meola G, Moxley T. Exercise intolerance and muscle contracture. In: Serratrice G, Pouget J, Azulay J-P, eds. Exercise Intolerance and Muscle Pain in Myotonic Disorder. Paris: Springer; 1999:133-141.</Citation>
        </Reference>
        <Reference>
          <Citation>Soyka M. Buprenorphine use ad risk of abuse and diversion. Adv Pharmacoepidemiol Drug Saf. 2014;3:145.</Citation>
        </Reference>
        <Reference>
          <Citation>Leffler A, Frank G, Kistner K, et al. Local anesthetic-like inhibition of voltage-gated Na(+) channels by the partial μ-opioid receptor agonist buprenorphine C. Anesthesiology. 2012;16:1335-1346.</Citation>
        </Reference>
        <Reference>
          <Citation>Fournier E, Arzel M, Sternberg D, et al. Electromyography guides toward subgroups of mutations in muscle channelopathies. Ann Neurol. 2004;56:650-661.</Citation>
        </Reference>
        <Reference>
          <Citation>Fournier E, Viala K, Gervais H, et al. Cold extends electromyography distinction between ion channel mutations causing myotonia. Ann Neurol. 2006;60:356-365.</Citation>
        </Reference>
        <Reference>
          <Citation>Michel P, Sternberg D, Jeannet PY, et al. Comparative efficacy of repetitive nerve stimulation, exercise, and cold in differentiating myotonic disorders. Muscle Nerve. 2007;36:643-650.</Citation>
        </Reference>
        <Reference>
          <Citation>Arnold WD, Kline D, Sanderson A, et al. Open-label trial of ranolazine for the treatment of myotonia congenita. Neurology. 2017;89:710-713.</Citation>
        </Reference>
        <Reference>
          <Citation>Lawless M, Arnold W, Agriesti J, et al. Investigation of ranolazine as an anti-myotonia treatment in myotonic dystrophy type 1. Neurology. 2018;90(suppl 15):P5.443.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
